ATOS
Atossa Therapeutics Inc.
$0.83
-$0.02(-2.10%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$109.63M
Volume
467.20K
52W Range
$0.55 - $1.66
Target Price
$5.63
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.8K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Total Revenue | $1.8K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-132.4K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $-130.7K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-12.6M | $-8.0M | $-7.6M | $-11.4M | $17.3M | $14.6M | $20.5M | $27.7M | $31.4M | $27.6M | ||
| Research & Development | $2.4M | $770.4K | $2.3M | $4.2M | $6.6M | $6.6M | $9.2M | $15.1M | $17.3M | $14.1M | ||
| Research Expense | $2.4M | $770.4K | $2.3M | $4.2M | $6.6M | $6.6M | $9.2M | $15.1M | $17.3M | $14.1M | ||
| Selling, General & Administrative | $10.3M | $6.5M | $4.9M | $7.2M | $10.6M | $8.0M | $11.3M | $12.6M | $14.0M | $13.5M | ||
| Selling & Marketing Expenses | $1.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $8.8M | $6.5M | $4.9M | $7.2M | $10.6M | $8.0M | $11.3M | $12.6M | $14.0M | $13.5M | ||
| Salaries & Wages | $-840.1K | $-876.2K | $-786.5K | $-1.1M | $-7.1M | -- | -- | -- | $4.6M | $2.3M | ||
| Depreciation & Amortization | $-73.1K | $-125.7K | $-26.0K | $-14.0K | $-22.0K | $19.0K | $10.0K | -- | -- | -- | ||
| Depreciation & Amortization | $-73.1K | $-125.7K | $192.8K | $-14.0K | $-22.0K | $19.0K | $10.0K | -- | -- | -- | ||
| Amortization | -- | -- | $-103.0K | $-30.0K | $-30.8K | $41.0K | $54.0K | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | $57.0K | $26.0K | $15.0K | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-12.8M | $-7.2M | $-7.4M | $-11.4M | $-17.3M | $-14.6M | $-20.5M | $-27.7M | $-31.4M | $-27.6M | ||
| EBITDA | $-12.5M | $-6.1M | $-8.0M | $-11.4M | $-17.2M | $-14.6M | $-20.5M | $-27.7M | $-30.1M | $-25.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Intinc | $431 | $1.6M | $154 | -- | -- | -- | $6.0K | $877.0K | $4.3M | $4.0M | ||
| Net Non-Operating Interest Income/Expense | $431 | $1.6M | $154 | -- | -- | -- | $6.0K | $877.0K | $4.3M | $4.0M | ||
| Gain on Sale of Securities | -- | $-163.3K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $670.9K | $719.0K | $742.3K | $-29.3K | $-25.6K | $2.3M | $91.0K | $-146.0K | $3.1M | $1.9M | ||
| Other Special Charges | -- | -- | $-280.6K | $29.3K | $25.6K | $-2.3M | $-91.0K | $-146.0K | $-70.0K | $-223.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | $163.3K | $-280.7K | -- | -- | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | $-163.3K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-12.8M | $-6.4M | $-8.1M | $-11.4M | $-17.2M | $-14.6M | $-20.5M | $-27.7M | $-30.1M | $-25.5M | ||
| Pre-Tax Income | $-12.8M | $-6.4M | $-8.1M | $-11.4M | $-17.2M | $-17.8M | $-20.6M | $-27.0M | $-30.1M | $-25.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-14.2K | $-12.0K | $-1.9M | -- | -- | -- | -- | -- | $-2.0K | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-12.8M | $-6.4M | $-8.1M | $-11.4M | $-17.2M | $-17.8M | $-20.6M | $-27.0M | $-30.1M | $-25.5M | ||
| Net Income (Continuing Operations) | $-12.8M | $-6.4M | $-8.1M | $-11.4M | $-17.2M | $-17.8M | $-20.6M | $-27.0M | $-30.1M | $-25.5M | ||
| Net Income (Discontinued Operations) | $-12.8M | $-6.4M | $-8.1M | $-11.4M | $-17.2M | $-17.8M | $-20.6M | $-27.0M | $-30.1M | $-25.5M | ||
| Net Income (Common Stockholders) | $-12.8M | $-6.4M | $-10.7M | $-22.9M | $-17.2M | $-22.3M | $-20.6M | $-27.0M | $-30.1M | $-25.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-23.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-12.8M | $-8.0M | $-7.6M | $-11.4M | $17.3M | $14.6M | $20.5M | $27.7M | $31.4M | $27.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $2.4M | $189.8K | $974.8K | $4.2M | $8.5M | $11.3M | $117.0K | $126.6M | $126.1M | $125.9M | ||
| Average Shares Outstanding (Diluted) | $1.9M | $189.6K | $743.8K | $2.1M | $8.5M | $11.3M | $117.0K | $126.6M | $126.1M | $125.9M | ||
| Shares Outstanding | $215.7K | $315.6K | $2.7M | $9.1M | $9.1M | $120.8M | $126.6M | $129.2M | $125.3M | $129.2M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-1.97 | $-0.18 | $-0.21 | $-0.24 | $-0.20 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-1.97 | $-0.18 | $-0.21 | $-0.24 | $-0.20 | ||
| Diluted EPS | $-6.6 | $-33.6 | $-10.92 | $-5.5 | $-2.03 | $-1.97 | $-0.18 | $-0.21 | $-0.24 | $-0.20 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-2.03 | -- | -- | -- | $-0.24 | $-0.20 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | $2.6M | $11.5M | -- | $4.5M | -- | -- | -- | -- | ||
| Allowances For Construction | -- | -- | $192.8K | -- | -- | -- | -- | -- | -- | -- | ||
| Depletion | -- | -- | $192.8K | -- | -- | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | $-1.2 | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | $-670.9K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $-3.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | $280.7K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $8.8M | $6.5M | $4.9M | $7.2M | $10.6M | $8.0M | $11.3M | $12.6M | $14.0M | $13.5M | ||
| Other Impairment Of Capital Assets | -- | $719.0K | $461.7K | -- | -- | -- | -- | -- | $3.0M | $1.7M | ||
| Otherunder Preferred Stock Dividend | -- | -- | $2.6M | $11.5M | -- | $4.5M | -- | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | $2.6M | $11.5M | -- | $4.5M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $8.8M | $6.5M | $4.9M | $7.2M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $1.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ATOS | $0.83 | -2.1% | 467.20K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Atossa Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW